1 in 5 boys got HPV shot in first year recommended

by Mike Stobbe

A new report offers a first look at how many boys are getting shots designed to protect girls from cervical cancer. Health officials say the number getting vaccinated so far is a good start.

The HPV vaccine has only been recommended for boys for about two years, and rates are usually low at first for new vaccines. But the government report released Thursday shows about 1 in 5 got at least one of the three vaccine doses last year.

The vaccine protects against , which can cause cervical cancer in girls and in both sexes. It was first recommended for girls but hasn't been all that popular. Health officials expect it to be a hard sell for boys, too.

More information: CDC report: www.cdc.gov/mmwr

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Report: Teen HPV vaccination rate still lagging

Jul 25, 2013

(AP)—Disappointed health officials say only about half of teenage girls have gotten a controversial vaccine against cervical cancer—a rate that's changed little in three years.

Sexually transmitted HPV declines in US teens

Jun 19, 2013

The number of US girls with the sexually transmitted disease HPV has dropped by about half even though relatively few youths are getting the vaccine, research showed on Wednesday.

Vaccinating boys plays key role in HPV prevention

Jul 22, 2013

Improving vaccination rates against the human papillomavirus (HPV) in boys is key to protecting both men and women, says new research from University of Toronto Professor Peter A. Newman from the Factor-Inwentash Faculty ...

Too few girls get HPV vaccine against cancer: CDC

Aug 30, 2012

(HealthDay)—Parents and doctors can do more to protect girls from cancers caused by the human papillomavirus (HPV), say U.S. health officials who are concerned by lagging HPV vaccination rates among females. ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments